Page last updated: 2024-11-06

shd 415g

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Femovan: drug combination consisting of gestodene and ethinyl estradiol [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID67387
SCHEMBL ID1650050
MeSH IDM0155917

Synonyms (18)

Synonym
femovan
minulet
femodene
18,19-dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17alpha)-, mixt. with (17alpha)-19-norpregna-1,3,5(10)-trien-20-yne-3,17-diol
shd 415g
harmonet
109852-02-0
shd415g
melodene
bay 86-5016
bay86-5016
ethinylestradiol/gestodene
gestodene/ee
mirelle
meliane
microgeste
SCHEMBL1650050
(8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14-decahydrocyclopenta[a]phenanthren-3-one;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"The effects of two cyclically administered, triphasic, combined low dosage oestrogen and progestogen oral contraceptives on haemostasis have been compared in a longitudinal study, over 6 months, in 26 healthy females aged 16-30 years."( A comparison of the effects of two triphasic oral contraceptives on haemostasis.
Cohen, H; Gillmer, MD; Machin, SJ; Mackie, IJ; Walshe, K, 1988
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (31)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (22.58)18.7374
1990's23 (74.19)18.2507
2000's1 (3.23)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.70 (24.57)
Research Supply Index3.89 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials15 (45.45%)5.53%
Reviews2 (6.06%)6.00%
Case Studies2 (6.06%)4.05%
Observational0 (0.00%)0.25%
Other14 (42.42%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]